Autopsy report · NCT02203604

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

“Insufficient rate of accrual”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 5 years 2 months before it stopped.
• 9 participants enrolled.
• Results were posted on the registry 3 years 5 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

CINJRegulatory

Sponsor type

University, hospital or other

Conditions

Recurrent Melanoma; Stage IIIA Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma

Interventions

aldesleukin; ipilimumab; laboratory biomarker analysis

Participants

9

Sites

6

Countries

United States

Trials that died the same way

• Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma
  “Insufficient accrual rate” (98% match in meaning)
• Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer
  “Accrual rate was too low” (88% match in meaning)
• A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI
  “Poor accrual rate” (88% match in meaning)
• OD-PHOENIX in Talus Osteochondral Lesion
  “Low accrual rate” (87% match in meaning)
• Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma
  “Insufficient accrual” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.